Last reviewed · How we verify

NCT06083012: COMRADE-AI

Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an AI Software During AF Ablation

Active, enrolled Last updated 15 January 2026
What this trial tests

trial testing Cardiac mapping in Atrial Fibrillation in 186 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
27 October 2023
Primary endpoint
27 April 2027
27 April 2027

Quick facts

Lead sponsorVolta Medical
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment186
Start date27 October 2023
Primary completion27 April 2027
Estimated completion27 April 2027
Sites7 locations across France, Germany

Drugs / interventions tested

Conditions studied

Sponsor

Volta Medical

Who can join

18 and older, any sex, with Atrial Fibrillation or Atrial Arrhythmia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this Observational Prospective Multi-center Study is to observe the acute and long-term safety and performance outcomes after spatiotemporal dispersion-based AF/AT ablation utilizing the Volta Medical AI software in "real-life" clinical practice, without any imposed clinical workflow. Moreover, this study will allow to collect medico-economic data related to the tailored ablation strategy guided by the Volta Medical AI software.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Volta Medical trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06083012.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing